Daniel B. Horton

2 months ago | ascpt.onlinelibrary.wiley.com | Ann McMahon |Daniel B. Horton |Yeruk Mulugeta |Lynne Yao

Perspective Pediatric Pharmacoepidemiology and Drug Development From a Regulatory Perspective Ann W. McMahon,  Corresponding Author Ann W. McMahon Office of Pediatric Therapeutics, Food and Drug Administration, Silver Spring, Maryland, USA Correspondence: Ann W. McMahon ([email protected])Search for more papers by this authorDaniel B. Horton,  Daniel B.

May 19, 2023 | onlinelibrary.wiley.com | Daniel B. Horton |Bruce C Carleton |Pharmaceutical Outcomes Programme |Madlen Gazarian

ORIGINAL ARTICLE This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/pds.5640.